tafamidis profile

tafamidis: may be effective in treating transthyretin amyloid polyneuropathy [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tafamidis : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazole-6-carboxylic acid in which the hydrogen at position 2 is replaced by a 3,5-dichlorophenyl group. Used (as its meglumine salt) for the amelioration of transthyretin-related hereditary amyloidosis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	11001318
CHEMBL ID	2103837
CHEBI ID	78538
SCHEMBL ID	442508
MeSH ID	M0543569

Synonym
2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid
3mi ,
tafamidis (jan/usan/inn)
D09673
594839-88-0
vyndamax (tn)
8fg9h9d31j ,
6-benzoxazolecarboxylic acid, 2-(3,5-dichlorophenyl)-
unii-8fg9h9d31j
vyndamax
tafamidis [usan:inn]
tafamidis
2-(3,5-dichlorophenyl)benzoxazole-6-carboxylic acid
fx-1006
137464-18-7
FT-0674793
4HIS
fx-1005
CHEMBL2103837
fx1006
chebi:78538 ,
S6465
tafamidis [usan]
tafamidis [jan]
tafamidis [mart.]
tafamidis [inn]
tafamidis [orange book]
tafamidis [who-dd]
tafamidis [mi]
HY-14852
SCHEMBL442508
AKOS017550076
tafamidisum
2-(3,5-dichlorophenyl)-6-benzoxazole carboxylic acid
c14h7cl2no3
gtpl8378
DTXSID00208185 ,
pf-06291826(tafamidis)
C75776
bdbm50197883
A869196
DB11644
BCP29089
Q519447
594839-88-0 (free acid)
Z1443584665
discontinued until pfizer approves it for our agreement
mfcd16621109
VS-0125
tafamidis-meglumine
HMS3741E09
NCGC00390731-01
2-(3,5-dichlorophenyl)benzo[d]oxazole-6-carboxylic acid
EN300-307185
EX-A3575
SY217402
tafamidis (mart.)
dtxcid20130676
2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid
n07xx08

Excerpt	Reference	Relevance
"Tafamidis is an effective treatment for patients with ATTR-CM, however its long-term effects on cardiac remodeling and cardiac amyloid deposition are unknown."	( Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study. Chao, CC; Cheng, MF; Chou, CH; Hsieh, ST; Hsueh, HW; Jyh-Ming Juang, J; Lee, MJ; Lin, YH; Shun, CT; Su, MY; Tsai, CH; Tseng, PH; Wu, YA; Yu, AL, 2023)	3.07
"Tafamidis is an effective treatment for transthyretin amyloid cardiomyopathy (ATTR-CM) in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT). "	( Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Damy, T; Garcia-Pavia, P; Gundapaneni, B; Hanna, M; Judge, DP; Merlini, G; Patterson, TA; Riley, S; Schwartz, JH; Sultan, MB; Witteles, R, 2021)	2.37
"Tafamidis is an effective treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), this study aimed to determine whether there is a differential effect between variant transthyretin amyloidosis (ATTRv) and wild-type transthyretin (ATTRwt)."	( Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT. Berk, JL; Boman, K; Damy, T; Elliott, P; Gundapaneni, B; Maurer, MS; Nativi-Nicolau, J; Patterson, TA; Rapezzi, C; Schwartz, JH; Sultan, MB; Velazquez, EJ, 2021)	2.44
"Tafamidis is a first-in-class, disease-modifying transthyretin (TTR) kinetic stabilizer that represents a major breakthrough in the treatment of transthyretin amyloidosis (ATTR amyloidosis)."	( Drug Discovery and Development in Rare Diseases: Taking a Closer Look at the Tafamidis Story. Bruno, M; Burton, A; Castaño, A; Judge, DP; Kelly, JW; Patel, JK; Riley, S; Schumacher, J; See Tai, S; Sultan, MB, 2021)	1.57
"tafamidis) is a treatment option."	( Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Ando, Y; Ishii, T; Koike, H; Misawa, S; Sekijima, Y; Ueda, M, 2018)	1.2
"Tafamidis is a TTR stabilizer that is orally administered and, by interfering with amyloid fibril formation and deposition, is capable of slowing progression of TTR polyneuropathy and of early-stage cardiomyopathy."	( Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis. Bianchi, A; Mascalchi, M; Pastorelli, F; Rapezzi, C; Salvi, F; Vella, A; Volpe, R, 2018)	1.59
"Tafamidis is a transthyretin (TTR) stabilizer able to prevent TTR tetramer dissociation. "	( Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. Bisogni, G; Calabrese, D; Cavallaro, T; Cortese, A; Fabrizi, GM; Gemelli, C; Gentile, L; Grandis, M; Lozza, A; Luigetti, M; Manganelli, F; Mauro, A; Mazzeo, A; Obici, L; Pareyson, D; Perlini, S; Piscosquito, G; Pradotto, LG; Russo, M; Sabatelli, M; Santoro, L; Schenone, A; Stancanelli, C; Vita, G, 2016)	2.15
"Tafamidis is a transthyretin (TTR) stabilizer recently approved to slow the neurologic impairment in TTR familial amyloid polyneuropathy (TTR-FAP). "	( Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study. Ayache, SS; Azoulay, D; Damy, T; Feray, C; Gorram, F; Le Corvoisier, P; Lefaucheur, JP; Nordine, T; Planté-Bordeneuve, V; Salhi, H, 2017)	2.13
"Tafamidis is a first-in-class inhibitor of transthyretin amyloid fibril formation. "	( Development and validation of a liquid chromatography-tandem mass spectrometry method for the assay of tafamidis in rat plasma: Application to a pharmacokinetic study in rats. Choi, S; Hyun, HC; Jeong, JW; Kim, HR; Kim, YS; Koo, TS; Lee, JH; Oh, JH, 2017)	2.11
"Tafamidis meglumine is a novel medicine that has been shown to slow the progression of peripheral neurological impairment in patients with hereditary transthyretin amyloidosis (ATTR). "	( Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report. Ako, J; Fujita, T; Iida, Y; Ikeda, Y; Inomata, T; Ishii, S; Kaida, T; Kitamura, E; Koitabashi, T; Maekawa, E; Nabeta, T; Naruke, T; Sekijima, Y, )	3.02
"Tafamidis is a TTR stabilizer able to prevent TTR tetramer dissociation, and several studies have demonstrated its safety and efficacy at slowing the progression of neuropathy in FAP caused by the TTR Val30Met mutation."	( Treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a case report. Miyazaki, Y, 2017)	1.42
"Tafamidis is a small-molecule inhibitor that binds selectively to TTR in human plasma and kinetically stabilizes the tetrameric structure of both wild-type TTR and a number of different mutants."	( Tafamidis for transthyretin amyloidosis. de Lartigue, J, 2012)	2.54

Excerpt	Reference	Relevance
"Tafamidis has been used for treatment of transthyretin cardiac amyloidosis (ATTR-CA). "	( Follow-up Tc-99 m pyrophosphate cardiac scan for patients with transthyretin cardiac amyloidosis treated with tafamidis. Chang, CY; Hu, LH; Huang, WS; Lee, TH; Peng, NJ; Wang, YF, 2023)	2.56
"Tafamidis has been unsuccessful for cardiac or nerve involvement after the first seven months."	( Coronary ectasia in amyloid cardiomyopathy and neuropathy due to the transthyretin mutation c.323A>G. Finsterer, J; Gatterer, E; Rauschka, H; Stöllberger, C, )	0.85
"Tafamidis has been granted marketing authorization by the European Commission for the treatment of TTR-FAP and the U.S."	( Tafamidis for transthyretin amyloidosis. de Lartigue, J, 2012)	2.54

Excerpt	Reference	Relevance
"Tafamidis reduced all-cause mortality and cardiovascular-related hospitalizations and minimized patient-reported health status deterioration at 30 months in patients with transthyretin (ATTR) amyloidosis. "	( Association of Tafamidis With Health Status in Patients With ATTR Cardiac Amyloidosis: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial. Barsdorf, AI; Floden, L; Hanna, M; Kapadia, H; Maurer, MS; Nativi-Nicolau, J; Sperry, BW; Spertus, JA; Stewart, M; Wyrwich, KW, 2023)	2.71

Excerpt	Reference	Relevance
"Tafamidis treatment was introduced for approximately half of the study patients with ATTRwt CA in real-world practice. "	( Early Experience of Tafamidis Treatment in Japanese Patients With Wild-Type Transthyretin Cardiac Amyloidosis From the Kochi Amyloidosis Cohort. Baba, Y; Hamada, T; Hirota, T; Kitaoka, H; Kubo, T; Miyagawa, K; Noguchi, T; Ochi, Y; Sugiura, K; Yamasaki, N, 2022)	2.49
"Tafamidis treatment positively affects left ventricular (LV) structure and function and improves outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). "	( Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy. Badr Eslam, R; Beitzke, D; Binder, C; Bonderman, D; Camuz Ligios, L; Cherouny, B; Dachs, TM; Dalos, D; Duca, F; Hacker, M; Kastner, J; Loewe, C; Rettl, R; Schrutka, L; Wollenweber, T, 2023)	2.74
"tafamidis) is a treatment option."	( Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Ando, Y; Ishii, T; Koike, H; Misawa, S; Sekijima, Y; Ueda, M, 2018)	1.2
"Tafamidis treatment was generally well tolerated although 7 of 31 patients had bouts of diarrhea."	( Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Aarts, J; Falk, RH; Grogan, DR; Judge, DP; Lombardo, I; Maurer, MS; Mundayat, R; Packman, J; Quyyumi, AA, 2015)	2.58
"Tafamidis treatment effectively achieved and maintained TTR stabilization and was well tolerated. "	( Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Aarts, J; Falk, RH; Grogan, DR; Judge, DP; Lombardo, I; Maurer, MS; Mundayat, R; Packman, J; Quyyumi, AA, 2015)	3.3
"Treatment with tafamidis free acid 61 mg in ATTR-CM patients delays the deterioration of LA and LV longitudinal function, resulting in significant clinical benefits compared with natural history. "	( Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy. Badr Eslam, R; Binder, C; Bonderman, D; Camuz Ligios, L; Charwat-Resl, S; Cherouny, B; Dachs, TM; Dalos, D; Duca, F; Kastner, J; Mann, C; Rettl, R; Schrutka, L, 2023)	1.67
"Treatment with tafamidis in ATTR-CM patients results in a significant reduction in SUV retention index, associated with significant benefits for LV and RV function and cardiac biomarkers. "	( Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy. Badr Eslam, R; Beitzke, D; Binder, C; Bonderman, D; Camuz Ligios, L; Cherouny, B; Dachs, TM; Dalos, D; Duca, F; Hacker, M; Kastner, J; Loewe, C; Rettl, R; Schrutka, L; Wollenweber, T, 2023)	1.65
"Treatment with tafamidis is projected to produce substantial clinical benefit but would greatly exceed conventional cost-effectiveness thresholds at the current US list price. "	( Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. Arnold, SV; Baron, SJ; Bellows, BK; Cohen, DJ; Kazi, DS; Maurer, MS; Shah, SJ; Shen, C; Sperry, BW; Spertus, JA; Yeh, RW, 2020)	1.23
"Treatment with tafamidis meglumine was started."	( Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis. Bianchi, A; Mascalchi, M; Pastorelli, F; Rapezzi, C; Salvi, F; Vella, A; Volpe, R, 2018)	1.21

Excerpt	Reference	Relevance
"The misassembly of soluble proteins into toxic aggregates, including amyloid fibrils, underlies a large number of human degenerative diseases."	( AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Alhamadsheh, MM; Baranczak, A; Chan, WK; Connelly, S; Graef, IA; Kelly, JW; Liedtke, M; Park, MS; Penchala, SC; Powers, ET; Rappley, I; Reixach, N; Vogel, H; Wang, Y; Wilson, IA; Witteles, RM; Zhao, L, 2013)	0.39
" Seven patients (19%) were withdrawn for adverse effects."	( Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Adams, D; Ducot, B; Lacroix, C; Lozeron, P; Mincheva, Z; Théaudin, M, 2013)	0.67
" There were a total of 19 adverse events, including four febrile urinary tract infections and three severe diarrhoeas, with faecal incontinence in two."	( Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Adams, D; Ducot, B; Lacroix, C; Lozeron, P; Mincheva, Z; Théaudin, M, 2013)	0.67
" Most adverse events (AEs) were mild/moderate, with no discontinuations due to AEs."	( Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study. Ando, Y; Ikeda, S; Machii, K; Misumi, Y; Morita, H; Obayashi, K; Ohta, M; Sekijima, Y; Takata, A; Ueda, M; Yamashita, T, 2016)	0.82
" Tafamidis proved safe and well-tolerated."	( Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. Bisogni, G; Calabrese, D; Cavallaro, T; Cortese, A; Fabrizi, GM; Gemelli, C; Gentile, L; Grandis, M; Lozza, A; Luigetti, M; Manganelli, F; Mauro, A; Mazzeo, A; Obici, L; Pareyson, D; Perlini, S; Piscosquito, G; Pradotto, LG; Russo, M; Sabatelli, M; Santoro, L; Schenone, A; Stancanelli, C; Vita, G, 2016)	1.61
"Long-term tafamidis was associated with a favourable safety/tolerability profile, without any unexpected adverse events."	( Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amass, L; Barroso, FA; Ebede, B; Judge, DP; Li, H; Stewart, M; Sultan, MB, 2017)	1.14
" Data on patient demographic and clinical characteristics and adverse drug reactions (ADRs) were captured using case-report forms."	( Characteristics of Patients with Hereditary Transthyretin Amyloidosis and an Evaluation of the Safety of Tafamidis Meglumine in Japan: An Interim Analysis of an All-case Postmarketing Surveillance. Ando, Y; Hirano, Y; Ishii, T; Matsumoto, N; Sekijima, Y; Takata, A; Ueda, M, 2020)	0.77
" Incidence of adverse events in both tafamidis doses were comparable to placebo."	( Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Damy, T; Garcia-Pavia, P; Gundapaneni, B; Hanna, M; Judge, DP; Merlini, G; Patterson, TA; Riley, S; Schwartz, JH; Sultan, MB; Witteles, R, 2021)	1.2

Excerpt	Reference	Relevance
" The method was also assessed for its applicability to pharmacokinetic studies in rats."	( Development and validation of a liquid chromatography-tandem mass spectrometry method for the assay of tafamidis in rat plasma: Application to a pharmacokinetic study in rats. Choi, S; Hyun, HC; Jeong, JW; Kim, HR; Kim, YS; Koo, TS; Lee, JH; Oh, JH, 2017)	0.67
" The objective of this analysis was to develop a unified population pharmacokinetic (PK) model of tafamidis, which can describe the PK of various different formulations in healthy subjects as well as patients with TTR amyloidosis, and to understand effects of intrinsic and extrinsic factors on the PK variability."	( Population pharmacokinetic modelling and simulation of tafamidis in healthy subjects and patients with transthyretin amyloidosis. Harnisch, L; Huh, Y; Nicholas, T; Riley, S, 2021)	1.09
" Several protein conjugation strategies have been developed for half-life extension."	( Enhancing the Pharmacokinetic Profile of Interleukin 2 through Site-Specific Conjugation to a Selective Small-Molecule Transthyretin Ligand. Alhamadsheh, MM; Liang, D; Liu, F; Park, MS; Ul Amin, T, 2021)	0.62

Excerpt	Reference	Relevance
" The oral bioavailability of AG10, combined with additional desirable drug-like features, makes it a very promising candidate to treat TTR amyloid cardiomyopathy."	( AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Alhamadsheh, MM; Baranczak, A; Chan, WK; Connelly, S; Graef, IA; Kelly, JW; Liedtke, M; Park, MS; Penchala, SC; Powers, ET; Rappley, I; Reixach, N; Vogel, H; Wang, Y; Wilson, IA; Witteles, RM; Zhao, L, 2013)	0.39

Excerpt	Relevance	Reference
" Oral dosing in each of the three treatment periods was separated by a washout period of ≥ 14 days."	( The effect of tafamidis on the QTc interval in healthy subjects. Klamerus, KJ; Moller, R; Riley, S; Wang, R; Watsky, E, 2015)	0.78
" An alternative single solid oral dosage formulation (tafamidis 61-mg free acid capsules) was developed and introduced for patient convenience (approved in the United States, United Arab Emirates, and European Union)."	( The Bioequivalence of Tafamidis 61-mg Free Acid Capsules and Tafamidis Meglumine 4 × 20-mg Capsules in Healthy Volunteers. Le, VH; Lockwood, PA; O'Gorman, MT; Patterson, TA; Riley, S; Sultan, MB; Tankisheva, E; Wang, Q, 2020)	1.12
"Tafamidis meglumine (Vyndaqel) can be dosed at 20 or 80 mg QD."	( Tafamidis concentration required for transthyretin stabilisation in cerebrospinal fluid. Coelho, T; Jaeger, M; Kelly, JW; Powers, ET; Tsai, FJ, 2023)	3.8
"Tafamidis stabilises TTR in CSF to what is likely a clinically meaningful extent at CSF concentrations achieved by the normal tafamidis dosing regimen."	( Tafamidis concentration required for transthyretin stabilisation in cerebrospinal fluid. Coelho, T; Jaeger, M; Kelly, JW; Powers, ET; Tsai, FJ, 2023)	3.8

Role	Description
central nervous system drug	A class of drugs producing both physiological and psychological effects through a variety of mechanisms involving the central nervous system.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
1,3-benzoxazoles	Compounds based on a fused 1,3-oxazole and benzene bicyclic ring skeleton.
monocarboxylic acid	An oxoacid containing a single carboxy group.
dichlorobenzene	Any member of the class of chlorobenzenes carrying two chloro groups at unspecified positions.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	39.8107	0.0096	10.5250	35.4813	AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Transthyretin	Homo sapiens (human)	IC50 (µMol)	3.3713	0.1600	4.2921	10.0000	AID1322954; AID1331731; AID1331734; AID1755162; AID1774080; AID1810837; AID1888717
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Transthyretin	Homo sapiens (human)	Kd	0.4266	0.0030	1.3482	10.0000	AID1322956; AID1322957; AID1386000; AID1452013; AID1452019; AID1605601; AID1605604; AID1705463; AID1705464; AID1774086; AID1848635; AID1848652
Albumin	Homo sapiens (human)	Kd	2.4000	0.0893	3.3135	8.0000	AID1386001; AID1386002
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Albumin	Homo sapiens (human)	PB	21.4500	7.8000	7.8000	7.8000	AID1386024; AID1386025
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
eye development	Retinol-binding protein 4	Homo sapiens (human)
positive regulation of immunoglobulin production	Retinol-binding protein 4	Homo sapiens (human)
gluconeogenesis	Retinol-binding protein 4	Homo sapiens (human)
heart development	Retinol-binding protein 4	Homo sapiens (human)
visual perception	Retinol-binding protein 4	Homo sapiens (human)
maintenance of gastrointestinal epithelium	Retinol-binding protein 4	Homo sapiens (human)
lung development	Retinol-binding protein 4	Homo sapiens (human)
positive regulation of insulin secretion	Retinol-binding protein 4	Homo sapiens (human)
response to retinoic acid	Retinol-binding protein 4	Homo sapiens (human)
retinol transport	Retinol-binding protein 4	Homo sapiens (human)
retinol metabolic process	Retinol-binding protein 4	Homo sapiens (human)
glucose homeostasis	Retinol-binding protein 4	Homo sapiens (human)
embryonic organ morphogenesis	Retinol-binding protein 4	Homo sapiens (human)
embryonic skeletal system development	Retinol-binding protein 4	Homo sapiens (human)
cardiac muscle tissue development	Retinol-binding protein 4	Homo sapiens (human)
female genitalia morphogenesis	Retinol-binding protein 4	Homo sapiens (human)
negative regulation of cardiac muscle cell proliferation	Retinol-binding protein 4	Homo sapiens (human)
embryonic retina morphogenesis in camera-type eye	Retinol-binding protein 4	Homo sapiens (human)
uterus development	Retinol-binding protein 4	Homo sapiens (human)
vagina development	Retinol-binding protein 4	Homo sapiens (human)
urinary bladder development	Retinol-binding protein 4	Homo sapiens (human)
heart trabecula formation	Retinol-binding protein 4	Homo sapiens (human)
signal transduction	Transthyretin	Homo sapiens (human)
purine nucleobase metabolic process	Transthyretin	Homo sapiens (human)
cellular response to starvation	Albumin	Homo sapiens (human)
negative regulation of mitochondrial depolarization	Albumin	Homo sapiens (human)
cellular response to calcium ion starvation	Albumin	Homo sapiens (human)
cellular oxidant detoxification	Albumin	Homo sapiens (human)
transport	Albumin	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein binding	Retinol-binding protein 4	Homo sapiens (human)
retinal binding	Retinol-binding protein 4	Homo sapiens (human)
retinol binding	Retinol-binding protein 4	Homo sapiens (human)
retinol transmembrane transporter activity	Retinol-binding protein 4	Homo sapiens (human)
hormone activity	Transthyretin	Homo sapiens (human)
protein binding	Transthyretin	Homo sapiens (human)
identical protein binding	Transthyretin	Homo sapiens (human)
thyroid hormone binding	Transthyretin	Homo sapiens (human)
oxygen binding	Albumin	Homo sapiens (human)
DNA binding	Albumin	Homo sapiens (human)
fatty acid binding	Albumin	Homo sapiens (human)
copper ion binding	Albumin	Homo sapiens (human)
protein binding	Albumin	Homo sapiens (human)
toxic substance binding	Albumin	Homo sapiens (human)
antioxidant activity	Albumin	Homo sapiens (human)
pyridoxal phosphate binding	Albumin	Homo sapiens (human)
identical protein binding	Albumin	Homo sapiens (human)
protein-folding chaperone binding	Albumin	Homo sapiens (human)
exogenous protein binding	Albumin	Homo sapiens (human)
enterobactin binding	Albumin	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular region	Retinol-binding protein 4	Homo sapiens (human)
extracellular space	Retinol-binding protein 4	Homo sapiens (human)
extracellular exosome	Retinol-binding protein 4	Homo sapiens (human)
extracellular space	Retinol-binding protein 4	Homo sapiens (human)
extracellular region	Transthyretin	Homo sapiens (human)
extracellular space	Transthyretin	Homo sapiens (human)
azurophil granule lumen	Transthyretin	Homo sapiens (human)
extracellular exosome	Transthyretin	Homo sapiens (human)
extracellular space	Transthyretin	Homo sapiens (human)
extracellular region	Albumin	Homo sapiens (human)
extracellular space	Albumin	Homo sapiens (human)
nucleus	Albumin	Homo sapiens (human)
endoplasmic reticulum	Albumin	Homo sapiens (human)
endoplasmic reticulum lumen	Albumin	Homo sapiens (human)
Golgi apparatus	Albumin	Homo sapiens (human)
platelet alpha granule lumen	Albumin	Homo sapiens (human)
extracellular exosome	Albumin	Homo sapiens (human)
blood microparticle	Albumin	Homo sapiens (human)
protein-containing complex	Albumin	Homo sapiens (human)
cytoplasm	Albumin	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (154)

Assay ID	Title	Year	Journal	Article
AID1386004	Potency index, ratio of Kd for diflunisal to Kd for test compound for binding affinity to transthyretin (unknown origin) by ITC method	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1615478	Binding affinity to wild-type TTR (unknown origin) assessed as induction of chemical shift at A25 residue at 1:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1755167	Aqueous solubility of the compound in pH 6.8 JP2 fluid measured after 4 hrs by HPLC-UV analysis	2021	Bioorganic & medicinal chemistry, 08-15, Volume: 44	Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
AID1615449	Binding affinity to His6-tagged wild-type TTR (unknown origin) expressed in Escherichia coli BL21 star (DE3) at 0.5:1 ratio of test compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1755181	Cmax in Sprague-Dawley rat at 0.1 mg/kg, iv measured up to 8 hrs by LC-MS/MS analysis	2021	Bioorganic & medicinal chemistry, 08-15, Volume: 44	Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
AID1755183	AUC infinity in Sprague-Dawley rat at 0.1 mg/kg, iv measured up to 8 hrs by LC-MS/MS analysis	2021	Bioorganic & medicinal chemistry, 08-15, Volume: 44	Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
AID1452015	Inhibition human wild type TTR expressed in Escherichia coli BL-21 assessed as fibril formation at 14.4 uM incubated for 30 mins after 96 hrs by light scattering method relative to control	2017	Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18	Stilbene Boronic Acids Form a Covalent Bond with Human Transthyretin and Inhibit Its Aggregation.
AID1696717	Stabilization of human His-tagged TTR (Gly21 to Glu147) expressed in HEK293 cells assessed as reduction in acid-induced protein aggregation by measuring reduction in high molecular aggregates at 50 uM incubated for 72 hrs at pH 4 by Western blot analysis	2020	Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19	Discovery of Bispecific Antagonists of Retinol Binding Protein 4 That Stabilize Transthyretin Tetramers: Scaffolding Hopping, Optimization, and Preclinical Pharmacological Evaluation as a Potential Therapy for Two Common Age-Related Comorbidities.
AID1898642	Displacement of [125I]-T4 from human recombinant TTR expressed in Escherichia coli BL21(DE3) Star by gamma spectrometric analysis	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease.
AID1725432	Inhibition of amyloid beta aggregation in mouse N2a695 cells measured for 4 hrs by fluorescence correlation spectroscopic analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Brain Permeable Tafamidis Amide Analogs for Stabilizing TTR and Reducing APP Cleavage.
AID1486518	Inhibition of acid-induced wild type transthyretin (unknown origin) aggregation expressed in Escherichia coli pre-incubated for 30 mins before acid addition and further incubated for 72 hrs at 37 degC under dark conditions by UV-Vis spectrophotometry	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
AID1848637	Binding affinity to first binding site of wild type TTR (unknown origin) assessed as change in enthalpy by ITC analysis
AID1486520	Displacement of [125I]-triiodothyronine from thyroid hormone receptor in rat liver membrane homogenates incubated for 18 hrs by scintillation counting method	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
AID1322957	Binding affinity to recombinant human wild type TTR expressed in Escherichia coli BL21 (DE3) assessed as dissociation constants for second binding site of TTR by isothermal titration calorimetric method	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	A novel bis-furan scaffold for transthyretin stabilization and amyloid inhibition.
AID1896522	Binding affinity to human serum TTR assessed as target occupancy incubated for 6 hrs by fluorescence polarization assay	2022	Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22	Enhancing the Safety and Efficacy of PSMA-Based Small-Molecule Drug Conjugates by Linker Stabilization and Conjugation to Transthyretin Binding Ligand.
AID1615490	Binding affinity to wild-type TTR (unknown origin) assessed as chemical shift perturbation at protein dimer-dimer interface at 2:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1705464	Binding affinity to wild type TTR (unknown origin) assessed as Kd2 by isothermal titration calorimetry	2020	Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23	Transthyretin Amyloidogenesis Inhibitors: From Discovery to Current Developments.
AID1615473	Binding affinity to wild-type TTR (unknown origin) assessed as induction of confirmational change at L55 residue at 0.5:1 to 1:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1774080	Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio incubated for 1 week by absorbance method	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1386007	Binding affinity to transthyretin (unknown origin) assessed as free TdeltaS changes by ITC method	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1386032	Binding affinity to purified human transthyretin assessed as protein occupancy at 10 uM incubated for 6 hrs in pH 7.4 PBS buffer in presence of 70 uM IgG by fluorescent probe exclusion assay	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1331734	Inhibition of TTR V30M mutant (unknown origin) assessed as inhibition of acid-mediated amyloidogenesis by measuring fibril formation preincubated with enzyme followed by amyloidogenesis stimulation by adjusting pH to 4.4 measured after 72 hrs relative to	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	Systemic optimization and structural evaluation of quinoline derivatives as transthyretin amyloidogenesis inhibitors.
AID1615479	Binding affinity to wild-type TTR (unknown origin) assessed as induction of chemical shift at I26 residue at 1:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1615493	Binding affinity to wild-type TTR (unknown origin) assessed as chemical shift perturbation at BEF strands of outer beta sheet at 2:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1615505	Binding affinity to wild-type TTR (unknown origin) assessed as chemical shift perturbation at K9 residue at 2:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1615469	Binding affinity to wild-type TTR (unknown origin) assessed as increase in bound resonance at L55 residue at 0.5:1 to 1:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1810857	Stabilization of human plasma TTR assessed as inhibition of formation of high molecular weight forms of TTR with acetate buffer at pH 4 by measured at 50 uM after 72 hrs by acid-induced aggregation assay	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Identification of Transthyretin Tetramer Kinetic Stabilizers That Are Capable of Inhibiting the Retinol-Dependent Retinol Binding Protein 4-Transthyretin Interaction: Potential Novel Therapeutics for Macular Degeneration, Transthyretin Amyloidosis, and Th
AID1452016	Inhibition of human TTR V30M mutant expressed in Escherichia coli BL-21 assessed as fibril formation at 7.2 uM incubated for 30 mins measured after 96 hrs by light scattering method relative to control	2017	Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18	Stilbene Boronic Acids Form a Covalent Bond with Human Transthyretin and Inhibit Its Aggregation.
AID1615488	Negative cooperative binding affinity to wild-type biotinylated human TTR assessed as association rate at binding site-2 by surface plasmon resonance	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1755170	Protein binding in Sprague-Dawley rat plasma assessed as unbound fraction at 1 uM measured after 4 hrs by equilibrium dialysis assay	2021	Bioorganic & medicinal chemistry, 08-15, Volume: 44	Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
AID1386029	Binding affinity to purified human transthyretin assessed as protein occupancy at 10 uM incubated for 6 hrs in pH 7.4 PBS buffer in presence of 600 uM albumin by fluorescent probe exclusion assay	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1725430	Inhibition of gamma secretase in mouse N2a695 cells using Sb4 substrate incubated for 3 hrs by ELISA	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Brain Permeable Tafamidis Amide Analogs for Stabilizing TTR and Reducing APP Cleavage.
AID1755166	Aqueous solubility of the compound in pH 1.2 JP1 fluid measured after 4 hrs ny HPLC-UV analysis	2021	Bioorganic & medicinal chemistry, 08-15, Volume: 44	Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
AID1755168	Permeability of the compound at 10 uM measured after 4 hrs by PAMPA based LC-MS analysis	2021	Bioorganic & medicinal chemistry, 08-15, Volume: 44	Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
AID1810858	Stabilization of human plasma TTR assessed as fold reduction in amount of aggregate formation at 50 uM measured after 72 hrs by Western blotting analysis relative to control	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Identification of Transthyretin Tetramer Kinetic Stabilizers That Are Capable of Inhibiting the Retinol-Dependent Retinol Binding Protein 4-Transthyretin Interaction: Potential Novel Therapeutics for Macular Degeneration, Transthyretin Amyloidosis, and Th
AID1615507	Binding affinity to wild-type TTR (unknown origin) assessed as stabilization of hydrogen bond between A120 and Y114 by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1848652	Binding affinity to second binding site of wild type TTR (unknown origin) assessed as dissociation constant by ITC assay
AID1848655	Binding affinity to second binding site of wild type TTR (unknown origin) assessed as change in enthalpy by ITC analysis
AID1725427	Increase in APP fragmentation in mouse N2a695 cells at 10 uM incubated for 6 hrs by Western blot analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Brain Permeable Tafamidis Amide Analogs for Stabilizing TTR and Reducing APP Cleavage.
AID1755164	Metabolic stability in Sprague-Dawley rat liver microsomes assessed as residual rate at 1 uM preincubated for 5 mins followed by NADPH addition and measured after 30 mins by LC-MS/MS analysis	2021	Bioorganic & medicinal chemistry, 08-15, Volume: 44	Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
AID1386015	Dissociation constant, pKa of the compound	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1386024	Binding affinity to human serum albumin assessed as compound level bound to protein at 30 uM measured immediately after gel filtration	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1615486	Negative cooperative binding affinity to wild-type biotinylated human TTR assessed as association rate at binding site-1 by surface plasmon resonance	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1774082	Stabilization of TTR V3OM mutant (unknown origin) assessed as suppression of TTR tetramer dissociation at 3 uM incubated for 9 days by glutaraldehyde cross-linking assay based SDS-PAGE analysis relative to control	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1615484	Binding affinity to wild-type TTR (unknown origin) assessed as induction of chemical shift at V122 residue at 1:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1810837	Binding affinity to human plasma TTR tetramer assessed as displacement of diclofenac-coupled FITC by fluorescence polarization assay	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Identification of Transthyretin Tetramer Kinetic Stabilizers That Are Capable of Inhibiting the Retinol-Dependent Retinol Binding Protein 4-Transthyretin Interaction: Potential Novel Therapeutics for Macular Degeneration, Transthyretin Amyloidosis, and Th
AID1615450	Binding affinity to His6-tagged wild-type TTR (unknown origin) expressed in Escherichia coli BL21 star (DE3) at 2:1 ratio of test compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1386019	Binding affinity to transthyretin (unknown origin) in human serum assessed as protein stabilization at 10 uM in pH 7.4 urea buffer by Western blot	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1386002	Binding affinity to human serum albumin	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1386001	Binding affinity to human serum albumin by ITC method	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1452014	Inhibition of human wild type TTR expressed in Escherichia coli BL-21 assessed as fibril formation at 7.2 uM incubated for 30 mins measured after 96 hrs by light scattering method relative to control	2017	Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18	Stilbene Boronic Acids Form a Covalent Bond with Human Transthyretin and Inhibit Its Aggregation.
AID1774081	Stabilization of TTR V3OM mutant (unknown origin) assessed as suppression of TTR tetramer dissociation at 1 to 10 uM incubated for 9 days by glutaraldehyde cross-linking assay based SDS-PAGE analysis	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1385999	Binding affinity to transthyretin in dog serum assessed as protein stabilization at 10 uM by by Western blot	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1486519	Binding affinity to transthyretin in human blood plasma assessed as plasma binding selectivity by measuring stoichiometry of small molecule bound to TTR incubated for 24 hrs at 37 degC by RP-HPLC	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
AID1386030	Binding affinity to purified human transthyretin assessed as protein occupancy at 10 uM incubated for 6 hrs in pH 7.4 PBS buffer in presence of 25 uM transferrin by fluorescent probe exclusion assay	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1725441	Stabilization of recombinant dual FLAG-tagged wild type TTR (unknown origin) in plasma blood at < 30 uM incubated for 48 hrs by ion exchange chromatographic method	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Brain Permeable Tafamidis Amide Analogs for Stabilizing TTR and Reducing APP Cleavage.
AID1615492	Binding affinity to wild-type TTR (unknown origin) assessed as chemical shift perturbation at V121 residue at 2:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1452013	Competitive binding affinity to human wild type TTR expressed in Escherichia coli BL-21 assessed as equilibrium dissociation constant of second site in presence of ANS by spectrofluorometer	2017	Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18	Stilbene Boronic Acids Form a Covalent Bond with Human Transthyretin and Inhibit Its Aggregation.
AID1725431	Effect on TTR-induced amyloid beta aggregation inhibition in mouse N2a695 cells measured for 4 hrs by fluorescence correlation spectroscopic analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Brain Permeable Tafamidis Amide Analogs for Stabilizing TTR and Reducing APP Cleavage.
AID1386006	Binding affinity to transthyretin (unknown origin) assessed as free enthalpy changes by ITC method	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1807499	Binding affinity to human TTR in human serum assessed as target occupancy at 10 uM measured every 15 mins for 6 hrs by fluorescent probe exclusion selectivity assay	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Enhancing the Pharmacokinetic Profile of Interleukin 2 through Site-Specific Conjugation to a Selective Small-Molecule Transthyretin Ligand.
AID1755185	Volume of distribution at steady state in Sprague-Dawley rat at 0.1 mg/kg, iv measured up to 8 hrs by LC-MS/MS analysis	2021	Bioorganic & medicinal chemistry, 08-15, Volume: 44	Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
AID1696718	Stabilization of human His-tagged TTR (Gly21 to Glu147) expressed in HEK293 cells assessed as reduction in acid-induced protein aggregation by measuring increase in TTR monomer level at 50 uM incubated for 72 hrs at pH 4 by Western blot	2020	Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19	Discovery of Bispecific Antagonists of Retinol Binding Protein 4 That Stabilize Transthyretin Tetramers: Scaffolding Hopping, Optimization, and Preclinical Pharmacological Evaluation as a Potential Therapy for Two Common Age-Related Comorbidities.
AID1848657	Binding affinity to second binding site of wild type TTR (unknown origin) assessed as change in entropy by ITC analysis
AID1322953	Stabilization of wild type TTR tetramer in human plasma assessed as tetramer to total protein ratio preincubated overnight at 4 degC followed by further incubation at room temperature for 1 hr in presence of 4M urea by isoelectric focusing densitometric a	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	A novel bis-furan scaffold for transthyretin stabilization and amyloid inhibition.
AID1331733	Inhibition of TTR V30M mutant (unknown origin) assessed as inhibition of acid-mediated amyloidogenesis by measuring fibril formation at 3.6 uM preincubated with enzyme followed by amyloidogenesis stimulation by adjusting pH to 4.4 measured after 72 hrs re	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	Systemic optimization and structural evaluation of quinoline derivatives as transthyretin amyloidogenesis inhibitors.
AID1755182	Elimination half life in Sprague-Dawley rat at 0.1 mg/kg, iv measured up to 8 hrs by LC-MS/MS analysis	2021	Bioorganic & medicinal chemistry, 08-15, Volume: 44	Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
AID1386008	Binding affinity to transthyretin (unknown origin) in pH 7.4 PBS buffer assessed as protein occupancy at 1:1 compound to TTR ratio by fluorescent probe exclusion assay	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1615485	Binding affinity to wild-type TTR (unknown origin) assessed as induction of chemical shift at W79 residue at 1:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1615502	Binding affinity to wild-type TTR (unknown origin) assessed as formation of hydrogen bond between K76 and E89 at 2:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1615470	Binding affinity to wild-type TTR (unknown origin) assessed as induction of chemical shift at L55 residue at 0.5:1 to 1:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1755162	Inhibition of acid-mediated aggregation of TTR V30M mutant (unknown origin) expressed in Escherichia coli pretreated for 30 mins at pH 7 followed by protein dilution in acetate buffer and further incubated for 96 hrs at pH 4.6 by thioflavin-T fluorescence	2021	Bioorganic & medicinal chemistry, 08-15, Volume: 44	Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
AID1615477	Binding affinity to wild-type TTR (unknown origin) assessed as induction of chemical shift at R104 residue at 1:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1774086	Binding affinity to TTR V30M mutant (unknown origin) by isothermal titration calorimetry	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1322954	Stabilization of recombinant human wild type TTR expressed in Escherichia coli BL21 (DE3) assessed as inhibition of amyloid beta formation by measuring turbidity preincubated for 30 mins followed by lowering pH from 7.2 to 4.4 measured after 72 hrs by mic	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	A novel bis-furan scaffold for transthyretin stabilization and amyloid inhibition.
AID1331731	Inhibition of wild type TTR (unknown origin) assessed as inhibition of acid-mediated amyloidogenesis by measuring fibril formation preincubated with enzyme followed by amyloidogenesis stimulation by adjusting pH to 4.4 measured after 72 hrs relative to co	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	Systemic optimization and structural evaluation of quinoline derivatives as transthyretin amyloidogenesis inhibitors.
AID1452019	Binding affinity to wild type TTR (unknown origin) assessed as equilibrium dissociation constant of second site by isothermal titration calorimetry	2017	Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18	Stilbene Boronic Acids Form a Covalent Bond with Human Transthyretin and Inhibit Its Aggregation.
AID1725428	Increase in APP-CTF fragmentation in mouse N2a695 cells at 10 uM incubated for 6 hrs by Western blot analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Brain Permeable Tafamidis Amide Analogs for Stabilizing TTR and Reducing APP Cleavage.
AID1755163	Binding affinity to TTR V30M mutant (unknown origin) expressed in Escherichia coli by isothermal titration calorimetry	2021	Bioorganic & medicinal chemistry, 08-15, Volume: 44	Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
AID1888715	Inhibition of Transthyretin V30M mutant (unknown origin) assessed as acid mediated fibril formation at 1.8 uM measured after 72 hrs by UV-vis spectrophotometry	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Synthesis and biological evaluation of quinolone derivatives as transthyretin amyloidogenesis inhibitors and fluorescence sensors.
AID1331729	Inhibition of wild type TTR (unknown origin) assessed as inhibition of acid-mediated amyloidogenesis by measuring fibril formation at 7.2 uM preincubated with enzyme followed by amyloidogenesis stimulation by adjusting pH to 4.4 measured after 72 hrs rela	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	Systemic optimization and structural evaluation of quinoline derivatives as transthyretin amyloidogenesis inhibitors.
AID1615501	Binding affinity to wild-type TTR (unknown origin) assessed as chemical shift perturbation at E89 residue at 2:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1605605	Stabilization of wild type human transthyretin expressed in Escherichia coli BL21(DE3) Star assessed as reduction in fibril formation by measuring round particles and pre-fibrillar species levels at 50 uM pre-incubated with transthyretin for 1 hr before a
AID1486521	Displacement of [125I]-triiodothyronine from thyroid hormone receptor in rat liver membrane homogenates assessed as relative T3 displacement incubated for 18 hrs by scintillation counting method relative to control	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
AID1888712	Inhibition of wild-type Transthyretin (unknown origin) expressed in Escherichia coli expression system assessed as acid mediated fibril formation at 7.2 uM measured after 72 hrs by UV-vis spectrophotometry	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Synthesis and biological evaluation of quinolone derivatives as transthyretin amyloidogenesis inhibitors and fluorescence sensors.
AID1386010	Binding affinity to transthyretin in human serum assessed as protein stabilization at 2:1 compound to TTR ratio after 72 hrs by Western blot	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1774083	Stabilization of wild type TTR (unknown origin) expressed in Escherichia coli assessed as reduction in methanol-induced aggregation at 50 uM incubated for 60 min by absorbance method	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1810836	Disruption of retional-induced bacterially expressed MBP-tagged RBP4-TTR (unknown origin) protein-protein interaction measured by d2 dye based HTFR assay	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Identification of Transthyretin Tetramer Kinetic Stabilizers That Are Capable of Inhibiting the Retinol-Dependent Retinol Binding Protein 4-Transthyretin Interaction: Potential Novel Therapeutics for Macular Degeneration, Transthyretin Amyloidosis, and Th
AID1386003	Potency index, ratio of Kd for tolcapone to Kd for test compound for binding affinity to transthyretin (unknown origin) by ITC method	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1322964	Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by resazurin reduction assay	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	A novel bis-furan scaffold for transthyretin stabilization and amyloid inhibition.
AID1615476	Binding affinity to wild-type TTR (unknown origin) assessed as induction of chemical shift at R103 residue at 1:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1386025	Binding affinity to human serum albumin assessed as compound level bound to protein at 30 uM measured 124 hrs after dialysis	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1386033	Binding affinity to transthyretin in dog serum assessed as protein occupancy at 10 uM by fluorescent probe exclusion assay	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1615474	Binding affinity to wild-type TTR (unknown origin) assessed as induction of chemical shift at K15 residue at 1:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1386028	Binding affinity to purified human transthyretin assessed as protein occupancy at 10 uM incubated for 6 hrs in pH 7.4 PBS buffer by fluorescent probe exclusion assay	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1331732	Inhibition of TTR V30M mutant (unknown origin) assessed as inhibition of acid-mediated amyloidogenesis by measuring fibril formation at 7.2 uM preincubated with enzyme followed by amyloidogenesis stimulation by adjusting pH to 4.4 measured after 72 hrs re	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	Systemic optimization and structural evaluation of quinoline derivatives as transthyretin amyloidogenesis inhibitors.
AID1386000	Binding affinity to transthyretin (unknown origin) by ITC method	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1755165	Metabolic stability in Sprague-Dawley rat liver microsomes assessed as residual rate at 1 uM measured after 30 mins by LC-MS/MS analysis	2021	Bioorganic & medicinal chemistry, 08-15, Volume: 44	Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
AID1848635	Binding affinity to first binding site of wild type TTR (unknown origin) assessed as dissociation constant by ITC assay
AID1386012	Cmax in human at 80 mg qd	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1615452	Binding affinity to wild-type TTR (unknown origin) assessed as increase in bound resonance at D99 residue at 0.5:1 to 1:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1322965	Stabilization of TTR V30M mutant tetramer in human plasma assessed as tetramer to total protein ratio preincubated overnight at 4 degC followed by further incubation at room temperature for 1 hr in presence of 4M urea by isoelectric focusing densitometric	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	A novel bis-furan scaffold for transthyretin stabilization and amyloid inhibition.
AID1774078	Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 4 uM incubated for 1 week by absorbance method	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1774075	Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli assessed as ANS saturation ratio at 400 uM incubated for 1 hr in presence of 7.5 uM ANS by fluorescence method (Rvb = 56 +/- 2.3%)	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1386018	Binding affinity to transthyretin (unknown origin) in human serum assessed as protein occupancy at 200 uM by fluorescent probe exclusion assay	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1725434	Brain concentration in 5XFAD mouse at 50 mg/kg, po measured after 15 days by LC-MS/MS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Brain Permeable Tafamidis Amide Analogs for Stabilizing TTR and Reducing APP Cleavage.
AID1888717	Inhibition of urea-induced Transthyretin denaturation in human plasma preincubated for 1 hr followed by urea addition by Western blot analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Synthesis and biological evaluation of quinolone derivatives as transthyretin amyloidogenesis inhibitors and fluorescence sensors.
AID1615494	Binding affinity to wild-type TTR (unknown origin) assessed as chemical shift perturbation at AB loops at 2:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1615448	Binding affinity to His6-tagged wild-type TTR (unknown origin) expressed in Escherichia coli BL21 star (DE3) assessed as assignment of protein resonance by TROSY [1H-13C-15N] HNCA spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1605604	Stabilization of wild type human transthyretin expressed in Escherichia coli BL21(DE3) Star assessed as dissociation constant for TTR-amyloid beta (12 to 28) complex formation at 200 uM at 25 degC pre-incubated with transthyretin before amyloid beta (12 t
AID1848656	Binding affinity to first binding site of wild type TTR (unknown origin) assessed as change in entropy by ITC analysis
AID1322960	Displacement of [125I]-T4 from wild type TTR in human plasma after 1 hr by PAGE analysis	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	A novel bis-furan scaffold for transthyretin stabilization and amyloid inhibition.
AID1322956	Binding affinity to recombinant human wild type TTR expressed in Escherichia coli BL21 (DE3) assessed as dissociation constants for first binding site of TTR by isothermal titration calorimetric method	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	A novel bis-furan scaffold for transthyretin stabilization and amyloid inhibition.
AID1615487	Negative cooperative binding affinity to wild-type biotinylated human TTR assessed as dissociation rate at binding site-1 by surface plasmon resonance	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1774085	Stabilization of TTR V142I mutant (unknown origin) expressed in Escherichia coli assessed as reduction in trypsin-induced aggregation incubated for 3 to 4 days by absorbance method	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1386009	Binding affinity to transthyretin in human serum assessed as protein occupancy at 2:1 compound to TTR ratio after 72 hrs by fluorescent probe exclusion assay	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1615508	Binding affinity to wild-type TTR (unknown origin) assessed as stabilization of hydrogen bond between V121 and T106 by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1848654	Binding affinity to second binding site of wild type TTR (unknown origin) assessed as gibbs free energy change by ITC analysis
AID1386031	Binding affinity to purified human transthyretin assessed as protein occupancy at 10 uM incubated for 6 hrs in pH 7.4 PBS buffer in presence of 5 uM fibrinogen by fluorescent probe exclusion assay	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1331730	Inhibition of wild type TTR (unknown origin) assessed as inhibition of acid-mediated amyloidogenesis by measuring fibril formation at 3.6 uM preincubated with enzyme followed by amyloidogenesis stimulation by adjusting pH to 4.4 measured after 72 hrs rela	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	Systemic optimization and structural evaluation of quinoline derivatives as transthyretin amyloidogenesis inhibitors.
AID1615489	Negative cooperative binding affinity to wild-type biotinylated human TTR assessed as dissociation rate at binding site-2 by surface plasmon resonance	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1615471	Binding affinity to wild-type TTR (unknown origin) assessed as induction of confirmational change at D99 residue at 0.5:1 to 1:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1605603	Stabilization of wild type human transthyretin expressed in Escherichia coli BL21(DE3) Star assessed as fibril formation at 50 uM pre-incubated with transthyretin before amyloid beta (1 to 42) addition by ThT fluorescence assay (Rvb = 25 +/- 1%)
AID1774076	Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli at 400 uM incubated for 1 hr in presence of 75 uM ANS by fluorescence method (Rvb = 91 +/- 0.92%)	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1810859	Stabilization of human plasma TTR assessed as increase in dimer band intensity at 50 uM measured after 72 hrs by Western blotting analysis	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Identification of Transthyretin Tetramer Kinetic Stabilizers That Are Capable of Inhibiting the Retinol-Dependent Retinol Binding Protein 4-Transthyretin Interaction: Potential Novel Therapeutics for Macular Degeneration, Transthyretin Amyloidosis, and Th
AID1888714	Inhibition of Transthyretin V30M mutant (unknown origin) assessed as acid mediated fibril formation at 3.6 uM measured after 72 hrs by UV-vis spectrophotometry	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Synthesis and biological evaluation of quinolone derivatives as transthyretin amyloidogenesis inhibitors and fluorescence sensors.
AID1615480	Binding affinity to wild-type TTR (unknown origin) assessed as induction of chemical shift at S52 residue at 1:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1331735	Inhibition of wild type TTR (unknown origin) assessed as inhibition of acid-mediated amyloidogenesis by measuring reduction in fibril formation at 3.6 uM preincubated with enzyme followed by amyloidogenesis stimulation by adjusting pH to 4.4 measured up t	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	Systemic optimization and structural evaluation of quinoline derivatives as transthyretin amyloidogenesis inhibitors.
AID1755186	AUC (0 to 8 hrs) in Sprague-Dawley rat at 0.1 mg/kg, iv measured up to 8 hrs by LC-MS/MS analysis	2021	Bioorganic & medicinal chemistry, 08-15, Volume: 44	Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
AID1705463	Binding affinity to wild type TTR (unknown origin) assessed as Kd1 by isothermal titration calorimetry	2020	Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23	Transthyretin Amyloidogenesis Inhibitors: From Discovery to Current Developments.
AID1755184	Total clearance in Sprague-Dawley rat at 0.1 mg/kg, iv measured up to 8 hrs by LC-MS/MS analysis	2021	Bioorganic & medicinal chemistry, 08-15, Volume: 44	Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
AID1615468	Binding affinity to wild-type TTR (unknown origin) assessed as increase in bound resonance at S117 residue at 0.5:1 to 1:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1615481	Binding affinity to wild-type TTR (unknown origin) assessed as induction of chemical shift at H90 residue at 1:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1452017	Inhibition of human TTR V30M mutant expressed in Escherichia coli BL-21 assessed as fibril formation at 14.2 uM incubated for 30 mins measured after 96 hrs by light scattering method relative to control	2017	Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18	Stilbene Boronic Acids Form a Covalent Bond with Human Transthyretin and Inhibit Its Aggregation.
AID1755187	Bioavailability in Sprague-Dawley rat at 0.1 mg/kg, iv measured up to 8 hrs by LC-MS/MS analysis	2021	Bioorganic & medicinal chemistry, 08-15, Volume: 44	Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
AID1848653	Binding affinity to first binding site of wild type TTR (unknown origin) assessed as gibbs free energy change by ITC analysis
AID1755190	AUC (0 to 8 hrs) in Sprague-Dawley rat at 0.1 mg/kg, po measured up to 8 hrs by LC-MS/MS analysis	2021	Bioorganic & medicinal chemistry, 08-15, Volume: 44	Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
AID1386005	Binding affinity to transthyretin (unknown origin) assessed as free energy changes by ITC method	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
AID1725433	Plasma concentration in 5XFAD mouse at 50 mg/kg, po measured after 15 days by LC-MS/MS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Brain Permeable Tafamidis Amide Analogs for Stabilizing TTR and Reducing APP Cleavage.
AID1755189	Tmax in Sprague-Dawley rat at 0.1 mg/kg, po measured up to 8 hrs by LC-MS/MS analysis	2021	Bioorganic & medicinal chemistry, 08-15, Volume: 44	Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
AID1755188	Cmax in Sprague-Dawley rat at 0.1 mg/kg, po measured up to 8 hrs by LC-MS/MS analysis	2021	Bioorganic & medicinal chemistry, 08-15, Volume: 44	Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
AID1615475	Binding affinity to wild-type TTR (unknown origin) assessed as induction of chemical shift at L17 residue at 1:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1615483	Binding affinity to wild-type TTR (unknown origin) assessed as induction of chemical shift perturbation at A120 residue at 1:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1605601	Stabilization of wild type human transthyretin expressed in Escherichia coli BL21(DE3) Star assessed as dissociation constant for TTR-amyloid beta (1 to 42) complex formation at 200 uM at 25 degC pre-incubated with transthyretin before amyloid beta (1 to
AID1615472	Binding affinity to wild-type TTR (unknown origin) assessed as induction of confirmational change at S117 residue at 0.5:1 to 1:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1615495	Binding affinity to wild-type TTR (unknown origin) assessed as chemical shift perturbation at BC loops at 2:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1615504	Binding affinity to wild-type TTR (unknown origin) assessed as chemical shift perturbation at A91 residue at 2:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1888713	Inhibition of wild-type Transthyretin (unknown origin) expressed in Escherichia coli expression system assessed as acid mediated fibril formation at 3.6 uM measured after 72 hrs by UV-vis spectrophotometry	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Synthesis and biological evaluation of quinolone derivatives as transthyretin amyloidogenesis inhibitors and fluorescence sensors.
AID1615482	Binding affinity to wild-type TTR (unknown origin) assessed as induction of chemical shift at V94 residue at 1:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
AID1755169	Intrinsic clearance in Sprague-Dawley rat liver microsomes at 1 uM preincubated for 5 mins followed by NADPH addition and measured after 30 mins by LC-MS/MS analysis	2021	Bioorganic & medicinal chemistry, 08-15, Volume: 44	Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
AID1774079	Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 10 uM incubated for 1 week by absorbance method	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1810838	Displacement of [3H]-all trans retinol from human urine biotinylated RBP4 incubated for 16 hrs measured by Scintillation Proximity Assay	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Identification of Transthyretin Tetramer Kinetic Stabilizers That Are Capable of Inhibiting the Retinol-Dependent Retinol Binding Protein 4-Transthyretin Interaction: Potential Novel Therapeutics for Macular Degeneration, Transthyretin Amyloidosis, and Th
AID1346206	Human transthyretin (Carrier proteins)	2012	Proceedings of the National Academy of Sciences of the United States of America, Jun-12, Volume: 109, Issue:24	Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.
AID977611	Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB	2013	Proceedings of the National Academy of Sciences of the United States of America, Jun-11, Volume: 110, Issue:24	AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (0.47)	29.6817
2010's	101 (47.64)	24.3611
2020's	110 (51.89)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	25 (11.26%)	5.53%
Reviews	45 (20.27%)	6.00%
Case Studies	19 (8.56%)	4.05%
Observational	4 (1.80%)	0.25%
Other	129 (58.11%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
glycine [no description available]	2.1	1	0	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
nickel Nickel: A trace element with the atomic symbol Ni, atomic number 28, and atomic weight 58.69. It is a cofactor of the enzyme UREASE.. nickel ion : A nickel atom having a net electric charge.. nickel atom : Chemical element (nickel group element atom) with atomic number 28.	2.06	1	0	metal allergen; nickel group element atom	epitope; micronutrient
diphosphoric acid diphosphoric acid : An acyclic phosphorus acid anhydride obtained by condensation of two molecules of phosphoric acid.	3.3	3	0	acyclic phosphorus acid anhydride; phosphorus oxoacid	Escherichia coli metabolite
albuterol Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.. albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).	2.31	1	0	phenols; phenylethanolamines; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; environmental contaminant; xenobiotic
amlexanox amlexanox: SRA-A antagonist;structure given in first source. amlexanox : A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position.	2.31	1	0	monocarboxylic acid; pyridochromene	anti-allergic agent; anti-ulcer drug; non-steroidal anti-inflammatory drug
benzbromarone Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.. benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.	2.25	1	0	1-benzofurans; aromatic ketone	uricosuric drug
bithionol Bithionol: Halogenated anti-infective agent that is used against trematode and cestode infestations.. bithionol : An aryl sulfide that is diphenyl sulfide in which each phenyl group is substituted at position 2 by hydroxy and at positions 3 and 5 by chlorine. A fungicide and anthelmintic, it was used in various topical drug products for the treatment of liver flukes, but withdrawn after being shown to be a potent photosensitizer with the potential to cause serious skin disorders.	2.31	1	0	aryl sulfide; bridged diphenyl antifungal drug; bridged diphenyl fungicide; dichlorobenzene; organochlorine pesticide; polyphenol	antifungal agrochemical; antiplatyhelmintic drug
bromhexine Bromhexine: A mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p744). bromhexine : A substituted aniline that is 2,4-dibromoaniline which is substituted at position 6 by a [cyclohexyl(methyl)amino]methyl group. It is used (as the monohydrochloride salt) as a mucolytic for the treatment of respiratory disorders associated with productive cough (i.e. a cough characterised by the production of sputum).	2.31	1	0	organobromine compound; substituted aniline; tertiary amino compound	mucolytic
buflomedil buflomedil: RN given refers to parent cpd; synonym LL 1656 refers to HCl; structure	2.31	1	0	aromatic ketone
carbinoxamine carbinoxamine: Note: tradenames that start with Histex refer to more than one drug. carbinoxamine : An organochlorine compound that is 2-(4-chlorobenzyl)pyridine in which one of the benzylic hydrogens is substituted by 2-(dimethylamino)ethoxy group. It is an ethanolamine-type antihistamine, used as its maleate salt for treating hay fever, as well as mild cases of Parkinson's disease.	2.31	1	0	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antiparkinson drug; H1-receptor antagonist; muscarinic antagonist
carvedilol [no description available]	2.41	1	0	carbazoles; secondary alcohol; secondary amino compound	alpha-adrenergic antagonist; antihypertensive agent; beta-adrenergic antagonist; cardiovascular drug; vasodilator agent
cetraxate [no description available]	2.31	1	0	benzenes; monocarboxylic acid
clioquinol Clioquinol: A potentially neurotoxic 8-hydroxyquinoline derivative long used as a topical anti-infective, intestinal antiamebic, and vaginal trichomonacide. The oral preparation has been shown to cause subacute myelo-optic neuropathy and has been banned worldwide.. 5-chloro-7-iodoquinolin-8-ol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.	2.31	1	0	monohydroxyquinoline; organochlorine compound; organoiodine compound	antibacterial agent; antifungal agent; antimicrobial agent; antineoplastic agent; antiprotozoal drug; chelator; copper chelator
clofoctol [no description available]	2.31	1	0	diarylmethane
cromolyn cromoglycic acid : A dicarboxylic acid that is the bis-chromone derivative of glycerol. It is effective as a mast cell stabilizer.	2.31	1	0	chromones; dicarboxylic acid	anti-asthmatic drug; calcium channel blocker
danthron danthron: structure. chrysazin : A dihydroxyanthraquinone that is anthracene-9,10-dione substituted by hydroxy groups at positions 1 and 8.	2.31	1	0	dihydroxyanthraquinone	apoptosis inducer; plant metabolite
diclofenac Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.	3.35	1	0	amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
dichlorophen Dichlorophen: Nontoxic laxative vermicide effective for taenia infestation. It tends to produce colic and nausea. It is also used as a veterinary fungicide, anthelmintic, and antiprotozoan. (From Merck, 11th ed.)	2.31	1	0	bridged diphenyl fungicide; diarylmethane
diflunisal Diflunisal: A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN.. diflunisal : An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position.	15.33	23	1	monohydroxybenzoic acid; organofluorine compound	non-narcotic analgesic; non-steroidal anti-inflammatory drug
emodin Emodin: Purgative anthraquinone found in several plants, especially RHAMNUS PURSHIANA. It was formerly used as a laxative, but is now used mainly as a tool in toxicity studies.. emodin : A trihydroxyanthraquinone that is 9,10-anthraquinone which is substituted by hydroxy groups at positions 1, 3, and 8 and by a methyl group at position 6. It is present in the roots and barks of numerous plants (particularly rhubarb and buckthorn), moulds, and lichens. It is an active ingredient of various Chinese herbs.	2.31	1	0	trihydroxyanthraquinone	antineoplastic agent; laxative; plant metabolite; tyrosine kinase inhibitor
flufenamic acid Flufenamic Acid: An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16). flufenamic acid : An aromatic amino acid consisting of anthranilic acid carrying an N-(trifluoromethyl)phenyl substituent. An analgesic and anti-inflammatory, it is used in rheumatic disorders.	4.01	3	0	aromatic amino acid; organofluorine compound	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
gemfibrozil [no description available]	2.31	1	0	aromatic ether	antilipemic drug
ifenprodil ifenprodil: NMDA receptor antagonist	2.31	1	0	piperidines
irsogladine irsogladine: RN given refers to parent cpd; MN 1695 refers to maleate salt	2.31	1	0	dichlorobenzene
labetalol Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.. labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.. 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.	2.31	1	0	benzamides; benzenes; phenols; primary carboxamide; salicylamides; secondary alcohol; secondary amino compound
meclofenamic acid Meclofenamic Acid: A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.. meclofenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,6-dichloro-3-methylphenyl group. A non-steroidal anti-inflammatory drug, it is used as the sodium salt for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis.	2.15	1	0	aminobenzoic acid; organochlorine compound; secondary amino compound	analgesic; anticonvulsant; antineoplastic agent; antipyretic; antirheumatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
mefenamic acid Mefenamic Acid: A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.. mefenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor. It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis.	2.15	1	0	aminobenzoic acid; secondary amino compound	analgesic; antipyretic; antirheumatic drug; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
metoclopramide Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.. metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.	2.31	1	0	benzamides; monochlorobenzenes; substituted aniline; tertiary amino compound	antiemetic; dopaminergic antagonist; environmental contaminant; gastrointestinal drug; xenobiotic
minoxidil Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371). minoxidil : A pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6.	2.31	1	0	dialkylarylamine; tertiary amino compound
moxisylyte Moxisylyte: An alpha-adrenergic blocking agent that is used in Raynaud's disease. It is also used locally in the eye to reverse the mydriasis caused by phenylephrine and other sympathomimetic agents. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1312)	2.31	1	0	monoterpenoid
nalidixic acid [no description available]	2.31	1	0	1,8-naphthyridine derivative; monocarboxylic acid; quinolone antibiotic	antibacterial drug; antimicrobial agent; DNA synthesis inhibitor
oxaprozin Oxaprozin: An oxazole-propionic acid derivative, cyclooxygenase inhibitor, and non-steroidal anti-inflammatory drug that is used in the treatment of pain and inflammation associated with of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; and ARTHRITIS, JUVENILE.. oxaprozin : A monocarboxylic acid that is a propionic acid derivative having a 4,5-diphenyl-1,3-oxazol-2-yl substituent at position 3. It is non-steroidal anti-inflammatory drug commonly used to relieve the pain and inflammatory responses associated with osteoarthritis and rheumatoid arthritis.	2.31	1	0	1,3-oxazoles; monocarboxylic acid	analgesic; non-steroidal anti-inflammatory drug
phloretin [no description available]	3.35	1	0	dihydrochalcones	antineoplastic agent; plant metabolite
pyrimethamine Maloprim: contains above 2 cpds	2.31	1	0	aminopyrimidine; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
1,2,5,8-tetrahydroxy anthraquinone 1,2,5,8-tetrahydroxy anthraquinone: structure in first source. quinalizarin : A tetrahydroxyanthraquinone having the four hydroxy groups at the 1-, 2-, 5- and 8-positions.	2.31	1	0	tetrahydroxyanthraquinone	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
risedronic acid Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.	2.31	1	0	pyridines
trimethoprim Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.	2.31	1	0	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic
thyroxine Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.. thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.	2.85	3	0	2-halophenol; iodophenol; L-phenylalanine derivative; non-proteinogenic L-alpha-amino acid; thyroxine zwitterion; thyroxine	antithyroid drug; human metabolite; mouse metabolite; thyroid hormone
leucine Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.	2.25	1	0	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.	6.78	3	2	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical
phenylalanine Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.	2.25	1	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; phenylalanine; proteinogenic amino acid	algal metabolite; EC 3.1.3.1 (alkaline phosphatase) inhibitor; Escherichia coli metabolite; human xenobiotic metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
valine Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.	6.78	3	2	L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid; valine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
alizarin [no description available]	2.31	1	0	dihydroxyanthraquinone	chromophore; dye; plant metabolite
tetrabromobisphenol a tetrabromobisphenol A: a brominated flame retardant. 3,3',5,5'-tetrabromobisphenol A : A bromobisphenol that is 4,4'-methanediyldiphenol in which the methylene hydrogens are replaced by two methyl groups and the phenyl rings are substituted by bromo groups at positions 2, 2', 6 and 6'. It is a brominated flame retardant.	2.13	1	0	brominated flame retardant; bromobisphenol
purpurin purpurin: from Rubiaceae plants; structure in first source. purpurin : A trihydroxyanthraquinone derived from anthracene by substitution with oxo groups at C-9 and C-10 and with hydroxy groups at C-1, C-2 and C-4.	2.31	1	0	trihydroxyanthraquinone	biological pigment; histological dye; plant metabolite
1,4-dihydroxyanthraquinone 1,4-dihydroxyanthraquinone: structure given in first source. quinizarin : A dihydroxyanthraquinone having the two hydroxy substituents at the 1- and 4-positions; formally derived from anthraquinone by replacement of two hydrogen atoms by hydroxy groups	2.31	1	0	dihydroxyanthraquinone	dye
diphenyl diphenyl: RN given refers to unlabeled cpd; structure	2.15	1	0	aromatic fungicide; benzenes; biphenyls	antifungal agrochemical; antimicrobial food preservative
4-phenylphenol 4-phenylphenol: RN given refers to cpd without isomeric designation. biphenyl-4-ol : A member of the class of hydroxybiphenyls that is biphenyl carrying a hydroxy group at position 4.	2.15	1	0	hydroxybiphenyls
4-nitrobiphenyl 4-nitrobiphenyl: structure given in first source	2.15	1	0	biphenyls
anthrarufin 1,5-dihydroxyanthraquinone: used in ferric ion sensing as an inclusion complex with beta-cyclodextrin; structure in first source. anthrarufin : A dihydroxyanthraquinone that is anthracene-9,10-dione substituted by hydroxy groups at positions 1 and 5.	2.31	1	0	dihydroxyanthraquinone
benzoxazoles 1,3-benzoxazole : A benzoxazole in which the benzene ring is fused to a 1,3-oxazole ring across positions 4 and 5.. benzoxazole : Compounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton.	20.28	195	40	1,3-benzoxazoles; mancude organic heterobicyclic parent
oxazoles Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.	2.06	1	0	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
thiazoles [no description available]	2.06	1	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
4-fluorobiphenyl [no description available]	2.15	1	0
diazomethane Diazomethane: A diazonium compound with the formula CH2N2.. diazomethane : The simplest diazo compound, in which a diazo group is attached to a methylene group.	2.15	1	0	diazo compound	alkylating agent; antineoplastic agent; carcinogenic agent; poison
rhein [no description available]	2.31	1	0	dihydroxyanthraquinone
aloe emodin aloe emodin: structure distinct from emodin; this does not mean emodin from aloe. Aloe emodin : A dihydroxyanthraquinone that is chrysazin carrying a hydroxymethyl group at position 3. It has been isolated from plant species of the genus Aloe.	2.31	1	0	aromatic primary alcohol; dihydroxyanthraquinone	antineoplastic agent; plant metabolite
chrysophanic acid chrysophanic acid: RN given refers to parent cpd; structure in Merck, 9th ed, #2260. chrysophanol : A trihydroxyanthraquinone that is chrysazin with a methyl substituent at C-3. It has been isolated from Aloe vera and exhibits antiviral and anti-inflammatory activity.	2.31	1	0	dihydroxyanthraquinone	anti-inflammatory agent; antiviral agent; plant metabolite
physcione physcione: structure. physcion : A dihydroxyanthraquinone that is 9,10-anthraquinone bearing hydroxy substituents at positions 1 and 8, a methoxy group at position 3, and a methyl group at position 6. It has been widely isolated and characterised from both terrestrial and marine sources.	2.31	1	0	dihydroxyanthraquinone	anti-inflammatory agent; antibacterial agent; antifungal agent; antineoplastic agent; apoptosis inducer; hepatoprotective agent; metabolite
3-hydroxybiphenyl 3-hydroxybiphenyl: structure given in first source. biphenyl-3-ol : A member of the class of hydroxybiphenyls that is phenol in which the hydrogen at position 3 has been replaced by a phenyl group.	2.15	1	0	hydroxybiphenyls
2,4,6-triiodophenol [no description available]	2.31	1	0
biphenyl-3-carboxylic acid biphenyl-3-carboxylic acid: structure in first source	2.15	1	0
olsalazine olsalazine: cpd with 2 salicylate molecules linked together by an azo bond. olsalazine : An azobenzene that consists of two molecules of 4-aminosalicylic acid joined by an azo linkage. A prodrug for mesalazine, an anti-inflammatory drug, it is used (as the disodium salt) in the treatment of inflammatory bowel disease.	2.31	1	0	azobenzenes; dicarboxylic acid	non-steroidal anti-inflammatory drug; prodrug
technetium Technetium: The first artificially produced element and a radioactive fission product of URANIUM. Technetium has the atomic symbol Tc, and atomic number 43. All technetium isotopes are radioactive. Technetium 99m (m=metastable) which is the decay product of Molybdenum 99, has a half-life of about 6 hours and is used diagnostically as a radioactive imaging agent. Technetium 99 which is a decay product of technetium 99m, has a half-life of 210,000 years.	2.9	2	0	manganese group element atom
diacerein diacerein: chelates with bivalent metals; a quinone which possesses redox properties; metabolized to active rhein; proposed mechanisms include inhibiting IL1 and metalloproteinases; called a slow acting symptomatic drug in osteoarthritis; no effect of cyclooxygenase;	2.31	1	0	anthraquinone
cephalexin Cephalexin: A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.. cephalexin : A semisynthetic first-generation cephalosporin antibiotic having methyl and beta-(2R)-2-amino-2-phenylacetamido groups at the 3- and 7- of the cephem skeleton, respectively. It is effective against both Gram-negative and Gram-positive organisms, and is used for treatment of infections of the skin, respiratory tract and urinary tract.	2.31	1	0	beta-lactam antibiotic allergen; cephalosporin; semisynthetic derivative	antibacterial drug
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	2.31	1	0	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
glutamic acid Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.	2.1	1	0	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
kc 400 KC 400: mixture of polychlorinated biphenyls. 3,3',5,5'-tetrachlorobiphenyl : A tetrachlorobiphenyl that is biphenyl in which both phenyl groups are substituted by chlorines at positions 3 and 5.	2.15	1	0	dichlorobenzene; tetrachlorobiphenyl
dobutamine Dobutamine: A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.. dobutamine : A catecholamine that is 4-(3-aminobutyl)phenol in which one of the hydrogens attached to the nitrogen is substituted by a 2-(3,4-dihydroxyphenyl)ethyl group. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used as the hydrochloride to increase the contractility of the heart in the management of acute heart failure.	2.31	1	0	catecholamine; secondary amine	beta-adrenergic agonist; cardiotonic drug; sympathomimetic agent
3,5-dichlorobiphenyl 3,5-dichlorobiphenyl : A dichlorobiphenyl that is 1,3-dichlorobenzene in which the hydrogen at position 5 has been replaced by a phenyl group.	2.15	1	0	dichlorobenzene; dichlorobiphenyl
bezafibrate [no description available]	2.31	1	0	aromatic ether; monocarboxylic acid amide; monocarboxylic acid; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
triclabendazole [no description available]	2.31	1	0	aromatic ether
nedocromil Nedocromil: A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with ASTHMA, including EOSINOPHILS; NEUTROPHILS; MACROPHAGES; MAST CELLS; MONOCYTES; AND PLATELETS.	2.31	1	0	dicarboxylic acid; organic heterotricyclic compound	anti-allergic agent; anti-asthmatic drug; non-steroidal anti-inflammatory drug
pioglitazone hydrochloride [no description available]	2.31	1	0	aromatic ether
bromfenac bromfenac: bromfenac sodium is the active cpd; structure in first source. bromfenac : Amfenac in which the the hydrogen at the 4 position of the benzoyl group is substituted by bromine. It is used for the management of ocular pain and treatment of postoperative inflammation in patients who have undergone cataract extraction. It was withdrawn from the US market in 1998, following concerns over off-label abuse and hepatic failure.	2.31	1	0	aromatic amino acid; benzophenones; organobromine compound; substituted aniline	non-narcotic analgesic; non-steroidal anti-inflammatory drug
fenofibric acid fenofibric acid: RN given refers to parent cpd without isomeric designation; structure. fenofibric acid : A monocarboxylic acid that is 2-methylpropanoic acid substituted by a 4-(4-chlorobenzoyl)phenoxy group at position 2. It is a metabolite of the drug fenofibrate.	2.31	1	0	aromatic ketone; chlorobenzophenone; monocarboxylic acid	drug metabolite; marine xenobiotic metabolite
epigallocatechin gallate epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.	3.35	1	0	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite
etofibrate etofibrate: analog of clofibrate with nicotinic acid substituted on the 2-carbon of the ethyl ester group; structure; RN given refers to parent cpd	2.31	1	0	monocarboxylic acid
4-phenylbenzoic acid 4-phenylbenzoic acid: RN given refers to 4-carboxylic cpd	2.15	1	0
9,10-anthraquinone 2-carboxylic acid 9,10-anthraquinone 2-carboxylic acid: structure in first source	2.31	1	0
biphenyl-2-carboxylic acid biphenyl-2-carboxylic acid: structure in first source	2.15	1	0
2-phenoxybenzoic acid phenoxybenzoic acid : An aromatic ether that is diphenyl ether in which one of the hydrogens is replaced by a carboxy group.. 2-phenoxybenzoic acid : A phenoxybenzoic acid in which the phenoxy group is ortho to the carboxy group.	2.15	1	0	phenoxybenzoic acid
3,3',5,5'-tetrachlorobiphenyl-4,4'-diol 3,3',5,5'-tetrachlorobiphenyl-4,4'-diol : A member of the class of hydroxybiphenyls formed formally by chlorination of biphenyl-4,4'-diol at C-3, -3', -5 and -5'.	2.54	2	0	dichlorobenzene; hydroxybiphenyls
nitisinone [no description available]	2.31	1	0	(trifluoromethyl)benzenes; C-nitro compound; cyclohexanones; mesotrione	EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor
febuxostat Febuxostat: A thiazole derivative and inhibitor of XANTHINE OXIDASE that is used for the treatment of HYPERURICEMIA in patients with chronic GOUT.. febuxostat : A 1,3-thiazolemonocarboxylic acid that is 4-methyl-1,3-thiazole-5-carboxylic acid which is substituted by a 3-cyano-4-(2-methylpropoxy)phenyl group at position 2. It is an orally-active, potent, and selective xanthine oxidase inhibitor used for the treatment of chronic hyperuricaemia in patients with gout.	2.06	1	0	1,3-thiazolemonocarboxylic acid; aromatic ether; nitrile	EC 1.17.3.2 (xanthine oxidase) inhibitor
docetaxel anhydrous Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.	2.41	1	0	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
dihydroresveratrol dihydroresveratrol: structure in first source. dihydroresveratrol : A stilbenol that is 1,1'-ethane-1,2-diyldibenzene with hydroxy groups at positions 1, 3 and 4'.	2.15	1	0	stilbenol	plant metabolite; xenobiotic metabolite
taurochenodeoxycholic acid Taurochenodeoxycholic Acid: A bile salt formed in the liver by conjugation of chenodeoxycholate with taurine, usually as the sodium salt. It acts as detergent to solubilize fats in the small intestine and is itself absorbed. It is used as a cholagogue and choleretic.. taurochenodeoxycholate : An organosulfonate oxoanion that is the conjugate base of taurochenodeoxycholic acid arising from deprotonation of the sulfonate OH group; major species at pH 7.3.. taurochenodeoxycholic acid : A bile acid taurine conjugate of chenodeoxycholic acid.	4.1	2	0	bile acid taurine conjugate	human metabolite; mouse metabolite
resveratrol trans-resveratrol : A resveratrol in which the double bond has E configuration.	2.55	2	0	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger
retinol Vitamin A: Retinol and derivatives of retinol that play an essential role in metabolic functioning of the retina, the growth of and differentiation of epithelial tissue, the growth of bone, reproduction, and the immune response. Dietary vitamin A is derived from a variety of CAROTENOIDS found in plants. It is enriched in the liver, egg yolks, and the fat component of dairy products.. vitamin A : Any member of a group of fat-soluble retinoids produced via metabolism of provitamin A carotenoids that exhibit biological activity against vitamin A deficiency. Vitamin A is involved in immune function, vision, reproduction, and cellular communication.. all-trans-retinol : A retinol in which all four exocyclic double bonds have E- (trans-) geometry.. retinol : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraen-1-ol substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).	2.25	1	0	retinol; vitamin A	human metabolite; mouse metabolite; plant metabolite
mycophenolic acid Mycophenolic Acid: Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.. mycophenolate : A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of mycophenolic acid.. mycophenolic acid : A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.	2.31	1	0	2-benzofurans; gamma-lactone; monocarboxylic acid; phenols	anticoronaviral agent; antimicrobial agent; antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; environmental contaminant; immunosuppressive agent; mycotoxin; Penicillium metabolite; xenobiotic
diethylstilbestrol Diethylstilbestrol: A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed). diethylstilbestrol : An olefinic compound that is trans-hex-3-ene in which the hydrogens at positions 3 and 4 have been replaced by p-hydroxyphenyl groups.	2.31	1	0	olefinic compound; polyphenol	antifungal agent; antineoplastic agent; autophagy inducer; calcium channel blocker; carcinogenic agent; EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; endocrine disruptor; xenoestrogen
melphalan Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.	3.35	1	0	L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
xanthohumol xanthohumol: from hop plant, Humulus lupulus. xanthohumol : A member of the class of chalcones that is trans-chalcone substituted by hydroxy groups at positions 4, 2' and 4', a methoxy group at position 6' and a prenyl group at position 3'. Isolated from Humulus lupulus, it induces apoptosis in human malignant glioblastoma cells.	3.35	1	0	aromatic ether; chalcones; polyphenol	anti-HIV-1 agent; antineoplastic agent; antiviral agent; apoptosis inducer; EC 2.3.1.20 (diacylglycerol O-acyltransferase) inhibitor; metabolite
pyrophosphate Diphosphates: Inorganic salts of phosphoric acid that contain two phosphate groups.	8.46	4	0	diphosphate ion
sulindac Sulindac: A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.. sulindac : A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions.	2.31	1	0	monocarboxylic acid; organofluorine compound; sulfoxide	analgesic; antineoplastic agent; antipyretic; apoptosis inducer; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug; tocolytic agent
dasatinib N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).	2.31	1	0	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
iododiflunisal iododiflunisal: an amyloid inhibitor; structure in first source	2.9	3	0
tolcapone Tolcapone: A benzophenone and nitrophenol compound that acts as an inhibitor of CATECHOL O-METHYLTRANSFERASE, an enzyme involved in the metabolism of DOPAMINE and LEVODOPA. It is used in the treatment of PARKINSON DISEASE in patients for whom levodopa is ineffective or contraindicated.. tolcapone : Benzophenone substituted on one of the phenyl rings at C-3 and C-4 by hydroxy groups and at C-5 by a nitro group, and on the other phenyl ring by a methyl group at C-4. It is an inhibitor of catechol O-methyltransferase.	5.73	8	0	2-nitrophenols; benzophenones; catechols	antiparkinson drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
luteolin [no description available]	2.31	1	0	3'-hydroxyflavonoid; tetrahydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist
vitamin k 1 Vitamin K 1: A family of phylloquinones that contains a ring of 2-methyl-1,4-naphthoquinone and an isoprenoid side chain. Members of this group of vitamin K 1 have only one double bond on the proximal isoprene unit. Rich sources of vitamin K 1 include green plants, algae, and photosynthetic bacteria. Vitamin K1 has antihemorrhagic and prothrombogenic activity.. phylloquinone : A member of the class of phylloquinones that consists of 1,4-naphthoquinone having methyl and phytyl groups at positions 2 and 3 respectively. The parent of the class of phylloquinones.	2.31	1	0	phylloquinones; vitamin K	cofactor; human metabolite; plant metabolite
4-hydroxystilbene 4-hydroxystilbene: RN given refers to cpd without isomeric designation. stilben-4-ol : A phenol having the structure of stilbene with a hydroxy function at C-4 of one of the phenyl rings; the stereochemistry across the alkene bond is not specified.	2.15	1	0	stilben-4-ol
gamma-mangostin gamma-mangostin : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3, 6 and 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antitumour activity.	2.31	1	0	phenols; xanthones	antineoplastic agent; plant metabolite; protein kinase inhibitor
technetium tc 99m pyrophosphate Technetium Tc 99m Pyrophosphate: A radionuclide imaging agent used primarily in scintigraphy or tomography of the heart to evaluate the extent of the necrotic myocardial process. It has also been used in noninvasive tests for the distribution of organ involvement in different types of amyloidosis and for the evaluation of muscle necrosis in the extremities.	2.82	2	0
n-(4-(2-methoxyphenoxy)phenyl)-n-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine: a metabotropic glutamate 2 receptor potentiator; structure in first source	2.31	1	0
ursodoxicoltaurine tauroursodeoxycholate : An organosulfonate oxoanion that is the conjugate base of tauroursodeoxycholic acid arising from deprotonation of the sulfonate OH group; major species at pH 7.3.. tauroursodeoxycholic acid : A bile acid taurine conjugate derived from ursoodeoxycholic acid.	4.1	2	0	bile acid taurine conjugate	anti-inflammatory agent; apoptosis inhibitor; bone density conservation agent; cardioprotective agent; human metabolite; neuroprotective agent
ns 1652 NS 1652: an anion conductance inhibitor; structure in first source	2.15	1	0
monomethyl auristatin e [no description available]	2.41	1	0
crizotinib Crizotinib: A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER.. crizotinib : A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)	2.31	1	0	3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine	antineoplastic agent; biomarker; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
oligonucleotides [no description available]	8.69	11	0
nuclear fast red nuclear fast red: structure in first source; do not confuse with nuclear fast red (basic dye). nuclear fast red : An organic sodium salt that is the monosodium salt of 4-amino-1,3-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-sulfonic acid. It forms bright red lakes with calcium and is a useful red nuclear staining lake with aluminum.	2.31	1	0	organic sodium salt	fluorochrome; histological dye
gdc 0449 HhAntag691: inhibits the hedgehog pathway and ABC transporters; has antineoplastic activity	2.05	1	0	benzamides; monochlorobenzenes; pyridines; sulfone	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist; teratogenic agent
cardiovascular agents Cardiovascular Agents: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.	4.78	4	0
abt-199 venetoclax: A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion; structure in first source.. venetoclax : A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion.	4.33	1	0	aromatic ether; C-nitro compound; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; N-sulfonylcarboxamide; oxanes; pyrrolopyridine	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	2.31	1	0	benzenes; hydroxycoumarin; methyl ketone
idarucizumab [no description available]	6.71	8	0
nitrophenols Nitrophenols: PHENOLS carrying nitro group substituents.	2.52	2	0
alizarine yellow g alizarine yellow G: binds bovine serum albumin; RN given refers to Na salt; structure given in first source	2.31	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Cardiomyopathies, Primary [description not available]	0	20.5	168	83
Amyloidosis A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits.	1	16.43	42	14
Cardiomyopathies A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).	1	22.5	168	83
Amyloid Neuropathy Type 1 [description not available]	0	22.04	252	105
Amyloid Neuropathies, Familial Inherited disorders of the peripheral nervous system associated with the deposition of AMYLOID in nerve tissue. The different clinical types based on symptoms correspond to the presence of a variety of mutations in several different proteins including transthyretin (PREALBUMIN); APOLIPOPROTEIN A-I; and GELSOLIN.	1	24.04	252	105
Age-Related Macular Degeneration [description not available]	0	2.25	1	0
Dry Macular Degeneration [description not available]	0	2.25	1	0
Macular Degeneration Degenerative changes in the RETINA usually of older adults which results in a loss of vision in the center of the visual field (the MACULA LUTEA) because of damage to the retina. It occurs in dry and wet forms.	0	2.25	1	0
Geographic Atrophy A form of MACULAR DEGENERATION also known as dry macular degeneration marked by occurrence of a well-defined progressive lesion or atrophy in the central part of the RETINA called the MACULA LUTEA. It is distinguishable from WET MACULAR DEGENERATION in that the latter involves neovascular exudates.	0	2.25	1	0
Acute Confusional Senile Dementia [description not available]	0	3.77	3	0
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	0	3.77	3	0
Cardiac Failure [description not available]	0	19.3	106	73
Cardiomyopathy, Restrictive A form of CARDIAC MUSCLE disease in which the ventricular walls are excessively rigid, impeding ventricular filling. It is marked by reduced diastolic volume of either or both ventricles but normal or nearly normal systolic function. It may be idiopathic or associated with other diseases (ENDOMYOCARDIAL FIBROSIS or AMYLOIDOSIS) causing interstitial fibrosis.	0	2.31	1	0
Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.	0	19.3	106	73
Cardiac Remodeling, Ventricular [description not available]	0	2.41	1	0
Polyneuropathy, Acquired [description not available]	0	8.16	10	1
Polyneuropathies Diseases of multiple peripheral nerves simultaneously. Polyneuropathies usually are characterized by symmetrical, bilateral distal motor and sensory impairment with a graded increase in severity distally. The pathological processes affecting peripheral nerves include degeneration of the axon, myelin or both. The various forms of polyneuropathy are categorized by the type of nerve affected (e.g., sensory, motor, or autonomic), by the distribution of nerve injury (e.g., distal vs. proximal), by nerve component primarily affected (e.g., demyelinating vs. axonal), by etiology, or by pattern of inheritance.	0	8.16	10	1
Left Ventricular Hypertrophy [description not available]	0	7.41	1	0
Hypertrophy, Left Ventricular Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.	0	2.41	1	0
Disease Exacerbation [description not available]	0	19.1	109	83
Auricular Fibrillation [description not available]	0	2.6	1	0
Atrial Fibrillation Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.	0	7.6	1	0
ANS (Autonomic Nervous System) Diseases [description not available]	0	3.12	1	0
Cardiac Diseases [description not available]	0	2.63	2	0
Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities.	0	2.63	2	0
Genetic Predisposition [description not available]	0	7.03	5	2
Chronic Illness [description not available]	0	2.21	1	0
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	0	2.21	1	0
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	0	2.21	1	0
Arrhythmia [description not available]	0	9.09	6	4
AL Amyloidosis [description not available]	0	6.53	4	0
Immunoglobulin Light-chain Amyloidosis A nonproliferative disorder of the PLASMA CELL characterized by excessive production and misfolding of IMMUNOGLOBULIN LIGHT CHAINS that form insoluble amyloid fibrils (see AMYLOID DEPOSITS) in various tissues. Clinical features include LIVER FAILURE; MULTIPLE MYELOMA; NEPHROTIC SYNDROME; RESTRICTIVE CARDIOMYOPATHY, and neuropathies.	0	6.53	4	0
Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.	0	9.09	6	4
Mitral Incompetence [description not available]	0	2.25	1	0
Mitral Valve Insufficiency Backflow of blood from the LEFT VENTRICLE into the LEFT ATRIUM due to imperfect closure of the MITRAL VALVE. This can lead to mitral valve regurgitation.	0	2.25	1	0
Amyloid Neuropathies Disorders of the peripheral nervous system associated with the deposition of AMYLOID in nerve tissue. Familial, primary (nonfamilial), and secondary forms have been described. Some familial subtypes demonstrate an autosomal dominant pattern of inheritance. Clinical manifestations include sensory loss, mild weakness, autonomic dysfunction, and CARPAL TUNNEL SYNDROME. (Adams et al., Principles of Neurology, 6th ed, p1349)	0	12.09	14	10
Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.	0	9.16	6	4
Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES.	0	10.19	3	1
Apoplexy [description not available]	0	7.74	4	4
Anterior Circulation Transient Ischemic Attack [description not available]	0	7.74	4	4
Cardiovascular Stroke [description not available]	0	7.74	4	4
Cardiac Arrest, Sudden [description not available]	0	7.74	4	4
Ischemic Attack, Transient Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)	0	7.74	4	4
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	0	7.74	4	4
Death, Sudden, Cardiac Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)	0	7.74	4	4
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	0	7.74	4	4
Orphan Diseases Rare diseases that have not been well studied.	0	3.57	2	0
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	0	4.15	1	0
Dementias, Transmissible [description not available]	0	3.23	1	0
Genetic Diseases [description not available]	0	2.15	1	0
Genetic Diseases, Inborn Diseases that are caused by genetic mutations present during embryo or fetal development, although they may be observed later in life. The mutations may be inherited from a parent's genome or they may be acquired in utero.	0	2.15	1	0
Nephritis Inflammation of any part of the KIDNEY.	0	3.53	1	1
Amyloidosis, Hereditary [description not available]	0	2.52	2	0
Amyloidosis, Familial Diseases in which there is a familial pattern of AMYLOIDOSIS.	1	4.52	2	0
Cyst [description not available]	0	2.15	1	0
Liver Dysfunction [description not available]	0	2.15	1	0
Liver Diseases Pathological processes of the LIVER.	0	2.15	1	0
Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.	0	2.17	1	0
Amyotrophy, Thenar, Of Carpal Origin [description not available]	0	3.09	1	0
Carpal Tunnel Syndrome Entrapment of the MEDIAN NERVE in the carpal tunnel, which is formed by the flexor retinaculum and the CARPAL BONES. This syndrome may be associated with repetitive occupational trauma (CUMULATIVE TRAUMA DISORDERS); wrist injuries; AMYLOID NEUROPATHIES; rheumatoid arthritis (see ARTHRITIS, RHEUMATOID); ACROMEGALY; PREGNANCY; and other conditions. Symptoms include burning pain and paresthesias involving the ventral surface of the hand and fingers which may radiate proximally. Impairment of sensation in the distribution of the median nerve and thenar muscle atrophy may occur. (Joynt, Clinical Neurology, 1995, Ch51, p45)	0	3.09	1	0
Brain Hemorrhage [description not available]	0	2.17	1	0
Amaurosis [description not available]	0	2.17	1	0
Cerebral Ischemia [description not available]	0	2.17	1	0
Brain Vascular Disorders [description not available]	0	2.17	1	0
Eye Disorders [description not available]	0	2.59	2	0
Siderosis A form of pneumoconiosis resulting from inhalation of iron in the mining dust or welding fumes.	0	2.17	1	0
Blindness The inability to see or the loss or absence of perception of visual stimuli. This condition may be the result of EYE DISEASES; OPTIC NERVE DISEASES; OPTIC CHIASM diseases; or BRAIN DISEASES affecting the VISUAL PATHWAYS or OCCIPITAL LOBE.	0	2.17	1	0
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	0	2.17	1	0
Cerebrovascular Disorders A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.	0	2.17	1	0
Eye Diseases Diseases affecting the eye.	0	2.59	2	0
Intracranial Hemorrhages Bleeding within the SKULL, including hemorrhages in the brain and the three membranes of MENINGES. The escape of blood often leads to the formation of HEMATOMA in the cranial epidural, subdural, and subarachnoid spaces.	0	2.17	1	0
Protein Aggregation, Pathological A biochemical phenomenon in which misfolded proteins aggregate either intra- or extracellularly. Triggered by factors such as MUTATION; POST-TRANSLATIONAL MODIFICATIONS, and environmental stress, it is generally associated with ALZHEIMER DISEASE; PARKINSON DISEASE; HUNTINGTON DISEASE; and TYPE 2 DIABETES MELLITUS.	0	2.54	2	0
Chronic Kidney Failure [description not available]	0	2.99	1	0
Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.	0	2.99	1	0
Electrocardiogram QT Prolonged [description not available]	0	4.41	1	1
Long QT Syndrome A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.	0	4.41	1	1
Cirrhosis [description not available]	0	3.5	1	1
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	0	3.5	1	1
Muscular Weakness [description not available]	0	2.11	1	0
Hypesthesia Absent or reduced sensitivity to cutaneous stimulation.	0	2.11	1	0
Muscle Weakness A vague complaint of debility, fatigue, or exhaustion attributable to weakness of various muscles. The weakness can be characterized as subacute or chronic, often progressive, and is a manifestation of many muscle and neuromuscular diseases. (From Wyngaarden et al., Cecil Textbook of Medicine, 19th ed, p2251)	0	2.11	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	2.13	1	0
Innate Inflammatory Response [description not available]	0	2.13	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	2.13	1	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	0	2.15	1	0
Protein Folding Diseases [description not available]	0	2.05	1	0
Adverse Drug Event [description not available]	0	2.05	1	0
Benign Neoplasms [description not available]	0	2.05	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	2.05	1	0
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	0	2.05	1	0

tafamidis

Description

Cross-References

Synonyms (60)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Bioavailability

Dosage Studied

Roles (1)

Drug Classes (3)

Protein Targets (4)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (29)

Molecular Functions (17)

Ceullar Components (13)

Bioassays (154)

Research

Studies (212)

Market Indicators

Research Demand Index: 77.46

Study Types

tafamidis

Description

Cross-References

Synonyms (60)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Bioavailability

Dosage Studied

Roles (1)

Drug Classes (3)

Protein Targets (4)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (29)

Molecular Functions (17)

Ceullar Components (13)

Bioassays (154)

Research

Studies (212)

Market Indicators

Research Demand Index: 77.46

Study Types

Related Drugs (119)

Related Conditions (90)